SCHEMBL8137325

SCHEMBL8137325

O=c1[nH]c(=O)c2cc(F)c(Cl)cc2[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.47
▸ KDM4E B2RXH2 3/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ HPGD P15428 2/20 0.47
▸ TDP1 Q9NUW8 1/20 0.44
▸ GPR84 Q9NQS5 1/20 0.42
▸ GRIN2D O15399 4/20 0.42
▸ GRIN3B O60391 4/20 0.42
▸ GRIN1 Q05586 4/20 0.42
▸ GRIN2A Q12879 4/20 0.42
▸ GRIN2B Q13224 4/20 0.42
▸ GRIN2C Q14957 4/20 0.42
▸ GRIN3A Q8TCU5 4/20 0.42
▸ GRIA1 P42261 3/20 0.42
▸ LMNA P02545 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ TSHR P16473 2/20 0.42
▸ THPO P40225 2/20 0.42
▸ PMP22 Q01453 2/20 0.42
▸ MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29909816 1.00 ALDH1A1 (0.47) ALDH1A1KDM4ESMN1; SMN2HPGDTDP1
SCHEMBL3426314 0.84 KDM4E (0.53) ALDH1A1KDM4ESMN1; SMN2HPGDGPR84
SCHEMBL3669922 0.84 GRIN2D (0.54) ALDH1A1KDM4ESMN1; SMN2HPGDGRIN2D
SCHEMBL1439986 0.82 ALDH1A1 (0.63) ALDH1A1KDM4ESMN1; SMN2HPGDTDP1
SCHEMBL29909400 0.78 ALDH1A1 (0.47) ALDH1A1KDM4ESMN1; SMN2HPGDGRIN2D
SCHEMBL2731858 0.78 ALDH1A1 (0.47) ALDH1A1KDM4ESMN1; SMN2HPGDGRIN2D
SCHEMBL5545956 0.78 KDM4E (0.47) ALDH1A1KDM4ESMN1; SMN2HPGDGRIN2D
SCHEMBL5368341 0.78 CA12 (0.53) ALDH1A1KDM4ESMN1; SMN2HPGDGRIN2D
SCHEMBL13804376 0.78 KDM4E (0.51) ALDH1A1KDM4ESMN1; SMN2HPGDGRIN2D
SCHEMBL13814616 0.78 KDM4E (0.47) ALDH1A1KDM4ESMN1; SMN2HPGDGRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026103888-A1 PYRIMIDIN-2(1H)-ONE DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 上海青润医药科技有限公司 2026-05-21 — — WO disclosed
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-11-27 — — US disclosed
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-12-05 — — US disclosed
EP-4445902-A2 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2024-10-16 — — EP disclosed
EP-4081305-B1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES INC (JP) 2024-09-18 — — EP disclosed
US-12054490-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2024-08-06 — — US disclosed
CN-118324767-A Diacylglycerol kinase modulating compounds 卡尔那生物科学株式会社 2024-07-12 — — CN disclosed
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-06-06 — — US disclosed
CN-115362003-B Diacylglycerol kinase modulating compounds 卡尔那生物科学株式会社 2024-03-22 — — CN disclosed
CN-117736207-A Diacylglycerol kinase modulating compounds 卡尔那生物科学株式会社 2024-03-22 — — CN disclosed
CN-115362003-A Diacylglycerol kinase modulating compounds 卡尔那生物科学株式会社 2022-11-18 — — CN disclosed
EP-4081305-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2022-11-02 — — EP disclosed
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 — — US disclosed
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 — — US disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 — — WO disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 — — WO disclosed
EP-0760819-B1 TRICYCLIC DICARBONYL DERIVATIVES HOFFMANN LA ROCHE (CH) 2000-07-19 — — EP disclosed
US-5688803-A BRAIN DISORDERS; PSYCHOLOGICAL DISORDERS HOFFMANN-LA ROCHE INC. (US) 1997-11-18 — — US disclosed
EP-0760819-A1 TRICYCLIC DICARBONYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1997-03-12 — — EP disclosed
WO-1995032205-A1 TRICYCLIC DICARBONYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1995-11-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK ALDH1A1 4095/4885KDM4E 1748/4885SMN1; SMN2 4737/4885
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK ALDH1A1 4095/4885KDM4E 1748/4885SMN1; SMN2 4737/4885
US-12054490-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK ALDH1A1 4095/4885KDM4E 1748/4885SMN1; SMN2 4737/4885
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK ALDH1A1 4095/4885KDM4E 1748/4885SMN1; SMN2 4737/4885
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK ALDH1A1 4095/4885KDM4E 1748/4885SMN1; SMN2 4737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback